Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with acute leukemia.
• People whose acute leukemia is complex or hard to treat — for example, those whose leukemia did not go into remission after 2 rounds of standard treatment, those who relapsed within 6 months of first remission, those who relapsed after 6 months but whose original treatment no longer worked, or those who have had a relapse at any point.
• People whose previous cancer treatments were finished at least 2 weeks ago (or 5 half-lives of the drug, whichever is shorter), with a longer gap required for certain immune-based treatments such as ipilimumab (confirm with trial site).
• People whose side effects from past cancer treatments have settled down to a mild level (grade 1 or lower), apart from minor issues like hair loss.
• People aged 15 to 64 years old.
• People with a general health and activity level rated between 0 and 3 on the ECOG scale, which measures how much a person's illness affects their daily life (confirm with trial site).
• People who do not have an active, uncontrolled infection or graft-versus-host disease (a complication that can occur after bone marrow or stem cell transplants).
• People whose doctors estimate they have a life expectancy of at least 3 months.
• People whose kidneys, liver, lungs, and heart are functioning well enough to meet specific medical thresholds — including kidney filtration rate, liver enzyme levels, heart pumping strength, blood oxygen levels, and no significant fluid around the lungs or heart (confirm with trial site for exact values).
• Women who are capable of becoming pregnant must have a negative pregnancy test before joining.

Who may not be able to join:

• People who have had another type of cancer in the past, unless they have been cancer-free for at least 3 years (some skin cancers and early-stage cancers may be assessed differently — confirm with trial site).
• People who have an active infection (fungal, bacterial, viral, or other) that is uncontrolled or suspected to be uncontrolled.
• People who have a known HIV infection.
• People with a known history of active hepatitis B or hepatitis C, unless specific blood test results show the virus is not active in the blood (confirm with trial site).
• People who have or have had a neurological or brain-related condition, such as seizures, stroke, dementia, or a brain-related autoimmune disease.
• People with serious heart conditions, such as uncontrolled irregular heartbeat, heart failure, or a heart attack within the past 6 months, or moderate to severe heart disease as classified by medical guidelines.
• People who have had a heart attack, heart procedure, stent placement, or unstable chest pain within the 12 months before joining.
• People whose cancer is growing so quickly that emergency medical treatment is likely to be needed within 6 weeks.
• People with a primary immune deficiency (a condition where the immune system does not work properly from birth or early life).
• People who have had a serious blood clot in a vein or the lungs within the past 6 months.
• People with any other medical condition that might affect the safety of the treatment or the accuracy of the study results.
• People who have had a severe allergic reaction to any of the drugs used in this study.
• People who have received a live vaccine within 6 weeks before starting the treatment preparation phase.
• Women who are pregnant or breastfeeding.
• People who are not willing or able to use effective contraception from the time of signing consent until 6 months after completing treatment.
• People who, in the opinion of the study doctor, may have difficulty completing all required visits, procedures, or follow-up appointments.
• People who have had autoimmune diseases causing organ damage (such as Crohn's disease, rheumatoid arthritis, or lupus), or who need ongoing immunosuppressive medication to manage a systemic condition.
• People who are currently participating in another clinical trial at the same time.

Important: Always verify eligibility with the trial site directly before applying.